Jazz Pharmaceuticals (JAZZ)Perpetual Ltd reduced its stake -37K shares

104K

Shares reported · -37K vs prior quarter

0.36%

Disclosed portfolio weight

$25.1M

Reported value

Holdings as of

Jun 30, 2026

Filed

Jul 15, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. May 22, 2026Insider · 2 peopleInsiders: 2 sales (~$1.1M)
2. May 25, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On May 25, 2026, Anne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc (the “Company”) 2026 annual meeting of shareholders, has informed the board of directors (the “Board”) that she will not stand for re-election.”
3. May 28, 2026Insider · 2 peopleInsiders: 2 sales (~$1.9M)
4. Jun 1, 2026InsiderDirector sold ~$1.41M of JAZZ shares in the open market
5. Jun 10, 2026InsiderOfficer sold ~$278K of JAZZ shares in the open market
6. Jun 15, 2026InsiderDirector sold ~$267K of JAZZ shares in the open market
7. Jul 1, 2026InsiderDirector sold ~$1.44M of JAZZ shares in the open market

What came next

1. Aug 3, 2026Company filing · Form 8-K · ResultsReported its results
2. Aug 3, 2026InsiderDirector sold ~$1.52M of JAZZ shares in the open market
3. Aug 10, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
4. Aug 26, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 2 more items)
5. Aug 27, 2026Insider · 1 personInsiders: 6 sales (~$19.2M)
6. Sep 1, 2026InsiderDirector sold ~$1.5M of JAZZ shares in the open market
7. Sep 8, 2026InsiderCEO sold ~$486K of JAZZ shares in the open market
8. Sep 10, 2026InsiderOfficer sold ~$289K of JAZZ shares in the open market
9. Sep 23, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
10. Oct 1, 2026InsiderDirector sold ~$1.38M of JAZZ shares in the open market
11. Oct 6, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 6, 2026, Samantha Pearce, Executive Vice President, Chief Commercial Officer of Jazz Pharmaceuticals plc (the “Company” ), notified the Company of her intent to retire from her role as Chief Commercial Officer upon the earlier of the selection and appointment of her successor or by June 30, 2027.”
12. Oct 6, 2026InsiderCEO sold ~$473K of JAZZ shares in the open market

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Jazz Pharmaceuticals

For Jazz Pharmaceuticals, OQRO holds 14 insider filings (SEC Form 4 or Form 144) and 10 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its JAZZ page.

How this filing works

• SEC Form 13F

Other disclosures at Jazz Pharmaceuticals

• SEC Form 144Oct 8, 2026
• SEC Form 4Oct 7, 2026
• SEC Form 4Oct 6, 2026
• SEC Form 144Oct 6, 2026
• SEC Form 4Sep 15, 2026
• SEC Form 4Sep 11, 2026

Everything OQRO holds on this company is on its JAZZ page.